News

Bio-IT World Conference 2014 - Recap

Learn what happened at Bio-IT World 2014: tranSMART awards, presentations, the community meeting and more.

 

Harvard Medical School and the Phelan-McDermid Syndrome Foundation Contract Leverages the tranSMART Open-source Knowledge Management Platform 

Wakefield, Massachusetts – July 21, 2014 – The tranSMART Foundation, a non-profit organization providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, announced today that the Phelan-McDermid Syndrome Foundation and the Center of Biomedical Informatics at Harvard Medical School were awarded a nearly $1 million contract from the Patient-Centered Outcomes Research Institute (PCORI) to  undertake an exciting research endeavor that will leverage the tranSMART platform. The team will collect and integrate previously-siloed medical and research data to advance knowledge and expedite research inquiries for families affected by Phelan-McDermid Syndrome (PMS), a very rare genetic condition with a moderate to severe impact on brain development and strong association with autism spectrum disorders.

The Phelan-McDermid Syndrome Data Network (PMS_DN) is one of 29 projects totaling $93.5 million in funding that together form PCORnet, the National Patient-Centered Clinical Research Network, a secure, national data network that will improve the speed, efficiency, and use of patient-centered comparative effectiveness research (CER).  Using tranSMART, the Natural Language Processing tool cTAKES and the i2b2 (Informatics for Integrating Biology and the Bedside) data model, the PMS_DN will provide an informatics backbone, helping researchers to mine diverse data sets and make and share meaningful insights with the PCORnet research partners.

“tranSMART is an amazing integration platform,” said Paul Avillach, MD, Ph.D.  co-PI of the PMS_DN project at the Center for Biomedical Informatics at Harvard Medical School.  “Using the functionality of i2b2 features in tranSMART, we are able to integrate patient and family-reported outcomes from the Phelan-McDermid Syndrome International Registry and electronic health records to help us effectively mine data and better understand PMS.”  

“I am thrilled by the robustness of tranSMART and the true passion brought by Dr. Paul Avillach and his team to leverage the technology to improve care and quality of life for our families,” said Megan O’Boyle, Principal Investigator for the PMS_DN on behalf of the Foundation and a parent of a child with Phelan-McDermid Syndrome. “Together we will build a rich data resource that will further attract researchers with new hypotheses not just about PMS, but about related conditions including autism spectrum and seizure disorders.”

“This project is an excellent example of the power our open-source platform has in enabling researchers from around the globe to easily collaborate and discover important insights in translational medicine,” said tranSMART Foundation CEO Keith Elliston. “With the powerful analytics produced by tranSMART and the scalable informatics framework of the i2b2 data model, Harvard and the Phelan-McDermid Syndrome Foundation will make great strides in PMS research.” 

About The tranSMART Foundation

 

The tranSMART Foundation is a non-profit organization that provides an open-source, cloud-based, data-sharing and analysis platform that enables scientists at universities, disease foundations, pharmaceutical companies, and government agencies around the world to share pre-competitive data in a way that saves money and time in translating research findings into new therapies and diagnostic tools.  Founded to steward the tranSMART platform, the Foundation is headquartered in Wakefield, Massachusetts with Centers of Excellence in Ann Arbor, Mich.; London, England; Boston, Mass.; and Amsterdam, Netherlands. The tranSMART Foundation can also be found on the web at www.tranSMARTFoundation.org.   

Contacts:

Karen Higgins
A&E Communications, Inc.
610-831-5723
khiggins@aandecomm.com 

 

The tranSMART Foundation Elects New Board of Directors

Board Includes Industry Leaders from the Top Life Science Companies and Educational Institutes

Wakefield, Massachusetts – June 2, 2014 – The tranSMART Foundation, a non-profit organization providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, announces its new board of directors comprised of industry leaders from the top life science companies and educational institutes. 

“With the scientific, technical and business expertise of the individuals on our board of directors and the support of their organizations, the Foundation is well-positioned to make a major impact on the development of new therapies and diagnostic tools,” said tranSMART Foundation CEO Keith Elliston. “This is a well-rounded group of prestigious industry and academic experts that will serve as a valuable resource for our leadership team providing us with guidance and support on our strategic initiatives, helping the Foundation to continue to grow and to gain momentum." 

The Foundation’s board of directors consists of 13 directors; 10 directors from its membership organizations and three at-large directors nominated by the management team and elected by the board.  Gold-level members of the Foundation elected six representatives from the Gold membership to serve on the board; Silver-level members elected two representatives from the Silver membership, and Bronze-level members elected two representatives from the Bronze membership to serve on the board of directors.  The members of the board of directors serve a one-year term and meet quarterly.

The new board of directors includes 

Gold:

  • Jamie Dananberg, M.D., Executive VP, Therapeutic Areas, Takeda Pharmaceuticals
  • Brett Davis, General Manager, ConvergeHEALTH by Deloitte and Principal, Deloitte Consulting
  • Matteo di Tomasso, VP Research Business Technology, Pfizer
  • Olivier Gien, Ph.D., Global Head, R&D Health Information Technologies, Sanofi
  • Juergen Hammer, Ph.D., MDA, Global Head Data Science; Center Head Pharmaceutical Research and Early Development Informatics, Roche TCRC
  • Jonathan Sheldon, Global VP, Health Sciences, Oracle 

Silver:

  • Gilbert Omenn, M.D., Ph.D., Director, Center for Computational Medicine and Bioinformatics (CCMB) and Professor, University of Michigan
  • Kenneth Pienta, M.D., The Donald S. Coffey Professor of Urology at the Brady Urological Institute of The John Hopkins Hospital

Bronze:

  • James Burns, Ph.D., Professor, Department of Microbiology and Immunology at the Drexel University College of Medicine
  • Lee Hood, M.D., Ph.D., President, Institute for Systems Biology

At Large:

  • Hiroaki Kitano, Ph.D., President, The Systems Biology Institute
  • Gerrit Meijer, Chair, Department of Pathology, VU University Medical Center Amsterdam, PI of CTMM TraIT
  • John Wilbanks, Chief Commons Officer, Sage Bionetworks

 

About The tranSMART Foundation

The tranSMART Foundation is a non-profit organization that provides an open-source, cloud-based, data-sharing and analysis platform that enables scientists at universities, disease foundations, pharmaceutical companies, and government agencies around the world to share pre-competitive data in a way that saves money and time in translating research findings into new therapies and diagnostic tools.  Founded to steward the tranSMART platform, the Foundation is headquartered in Wakefield, Massachusetts with Centers of Excellence in Ann Arbor, Mich.; London, England; Boston, Mass.; and Amsterdam, Netherlands. The tranSMART Foundation can also be found on the web at www.tranSMARTFoundation.org.v

Contacts:

Karen Higgins
A&E Communications, Inc.
610-831-5723
khiggins@aandecomm.com     

 

The tranSMART Foundation, U-BIOPRED and eTRIKS Win Bio-IT World Best Practices Award for U-BIOPRED Knowledge Portal

Wakefield, Massachusetts – May 28, 2014 – The tranSMART Foundation, a non-profit organization providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, and eTRIKS (European Translational Information and Knowledge Management Services), an organization supporting European projects in the area of knowledge management by using the tranSMART platform, today announced that the U-BIOPRED Project won the 2014 Bio-IT World Best Practices Award in the Research & Drug Discovery category.  The award was presented at the Bio-IT World Conference & Expo in Boston, Mass. on May 1.

Led by Academic Medical Centre, Amsterdam, U-BIOPRED (unbiased biomarkers for the prediction of respiratory disease outcomes) is a severe asthma research project with multiple stakeholders and funded (€21m) by EU-IMI (Innovative Medicines Initiative).  It was comprised of longitudinal clinical (adult and pediatric) studies and associated animal, in vitro and in silico model translational studies, using multi-omics technologies that attempted to produce novel classifiers better describing asthma disease heterogeneity.  Presented with numerous IT challenges related to the complexities of big data in biomedical and translational research, the U-BIOPRED Knowledge Portal leveraged the tranSMART v1.1 platform to enable data integration, analysis and project-wide access to 10 different datasets (clinical and omics).

“By developing the collaboration portal on the tranSMART platform, the consortium of 43 partners from industry and academia was able to eliminate redundancy and inconsistency during the process,” said tranSMART Foundation CEO Keith Elliston. “The U-BIOPRED project has assembled one of the largest and most detailed collection of patients with severe asthma.  The effort to organize the knowledge management platform in U-BIOPRED inspired IMI to fund eTRIKS, a €23.7m knowledge management project that is focused on developing a platform and services to manage its €2b investment.”

“The effort to establish the U-BIOPRED tranSMART platform required some dynamic thinking and collaboration on multiple levels,” explained Ioannis Pandis, postdoctoral fellow at Imperial College and one of the key drivers in making the platform happen.  “Complex translational research datasets are becoming the norm and it is efforts like these that are effectively sharing and analyzing the datasets that will harness the power of the ongoing data explosion.”

In addition to the data integration and analysis support provided by the tranSMART platform, the extended platform enabled the management of scientific hypothesis generation, analytic workflow and publication process, while also ensuring full transparency to a multi-stakeholder project.  This is the first real collaborative knowledge management platform in EU translational research.  Its success inspired the major investment to the knowledge management technology and service support in the EU IMI program through the funding of eTRIKS and EMIF projects totaling €100m for five years.

For more information on the U-BIOPRED project, watch this video or visit: www.ubiopred.eu.

About eTRIKS

eTRIKS is a knowledge management and service infrastructure project aimed at development of a
software and hardware system capable of the efficient storage and effective analysis of experimental data from studies in man, in animals and in pre-clinical models, maximizing the scientific knowledge that can be extracted from such studies. The project’s primary goal is to deliver a knowledge management system for ongoing and future IMI studies, such as U-BIOPRED, that require correlative analysis of both pre-clinical and clinical genome-scale biomarker data (genetics and genomics platforms) in conjunction with medical data from clinical trials. This open-source system will also be available for use outside of projects sponsored by IMI. For more information about the eTRIKS project go to - www.etriks.org.

About The tranSMART Foundation

The tranSMART Foundation is a non-profit organization that provides an open-source, cloud-based, data-sharing and analysis platform that enables scientists at universities, disease foundations, pharmaceutical companies, and government agencies around the world to share pre-competitive data in a way that saves money and time in translating research findings into new therapies and diagnostic tools.  Founded to steward the tranSMART platform, the Foundation is headquartered in Wakefield, Massachusetts with Centers of Excellence in Ann Arbor, Mich.; London, England; Boston, Mass.; and Amsterdam, Netherlands. The tranSMART Foundation can also be found on the web at www.tranSMARTFoundation.org.   

Contacts:

Karen Higgins
A&E Communications, Inc.
610-831-5723
khiggins@aandecomm.com 

 

Boehringer Ingelheim and Thomson Reuters Win CHI Poster Competition Award Leveraging the tranSMART Open Source Platform

Wakefield, Massachusetts – May 12, 2014 – The tranSMART Foundation, a non-profit organization providing a global, open-source knowledge management platform for scientists to share pre-competitive translational research data, announced today that a poster presented by Boehringer Ingelheim and Thomson Reuters at the 2014 Bio-IT World Conference based on the tranSMART platform won the CHI Poster Competition Award.   

Titled “A workflow based tranSMART system enabling scientists for fast and reliable genomic analysis”, the lead author of the poster was Yirong Wang, senior knowledge scientist at Boehringer Ingelheim.  Other contributors included Eugene Myshkin, Eugene Rakhmatulin and Sirimon O’Charoen of Thomson Reuters and William Loging of Boehringer Ingelheim. 

In partnership, Boehringer Ingelheim and Thomson Reuters leveraged the tranSMART open-source, knowledge management platform to create biSMART, a workflow-based system that addresses scientific questions in running data analysis, directly reducing the learning curve for scientists as well as the analysis time from days with traditional methods to just minutes.

“Based on the solid open-source platform (tranSMART), the new platform gives regular researchers the powerful discovery tool which was only available to bioinformaticians only a few years ago, to reduce analysis time from weeks to hours,” said Wang.  

“This collaboration between two industry leaders demonstrates the possibilities of the tranSMART open-source platform,” said tranSMART Foundation CEO Keith Elliston. “We congratulate Boehringer Ingelheim and Thomson Reuters on their award-winning poster.  Knowing that the tranSMART platform was the basis for their solution and the ability these technologies are giving scientists to more quickly and easily analyze data for translational medicine research is extremely satisfying.” 

 

About The tranSMART Foundation

The tranSMART Foundation is a non-profit organization that provides an open-source, cloud-based, data-sharing and analysis platform that enables scientists at universities, disease foundations, pharmaceutical companies, and government agencies around the world to share pre-competitive data in a way that saves money and time in translating research findings into new therapies and diagnostic tools.  Founded to steward the tranSMART platform, the Foundation is headquartered in Wakefield, Massachusetts with Centers of Excellence in Ann Arbor, Mich.; London, England; Boston, Mass.; and Amsterdam, Netherlands. The tranSMART Foundation can also be found on the web at www.tranSMARTFoundation.org.  

Contacts:

Karen Higgins
A&E Communications, Inc.
610-831-5723
khiggins@aandecomm.com 

 

The tranSMART Foundation and BT Collaborate to Deliver Fast, Flexible Cloud-Based Applications to Life Science Organizations

BT joins the tranSMART Foundation to extend support to the developer community; companies to continue work on the next release of Translational Medicine Platform

Wakefield, Massachusetts and Irving, Texas – April 30, 2014 – The tranSMART Foundation, a non-profit organization that pro- vides a global, open-source knowledge management platform for scientists to more easily share pre-competitive translational research data, and BT today announced that BT will join the tranSMART Foundation. This is an extension of their joint initiative announced last year to unlock the vast potential of cloud computing for the life sciences industry.

 With the extension of this partnership, the Foundation’s Translational Medicine Platform will continue to be offered on the BT for Life Sciences cloud service to scientists in research hospitals, academic research institutions and life science research organizations globally, as well as third-party organizations. As an affiliate member of the tranSMART Foundation, BT will be able to offer scientists and researchers access to a fast and flexible cloud-based platform that enables them share high-quality research data with colleagues around the world.

“BT’s continuing support for the Foundation’s objectives, is evident in its ongoing willingness to provide resources to the development community,” said tranSMART Foundation CEO Keith Elliston. “BT brings state-of-the-art, cloud-based hosting technology to the life sciences community on a worldwide basis – enabling scientists to benefit from shared research for drug discovery and development. BT has also recently helped to facilitate ‘Hackathons’, in February and April, to support coding teams from several organizations in working together to extend the platform and prepare for the upcoming 1.2 release.”

The tranSMART Foundation is expected to release the next version 1.2 of its open source data sharing and analysis platform this summer. This release will further increase productivity and efficiency of research and development initiatives, bringing together core branches from several groups into a single code stream. As part of the release, BT will continue to provide key cloud re- sources when the new version is available for demo, testing and downloading.

“Our life sciences customers need reliable access to ecosystems that can quickly process massive amounts of data and adapt to the natural ebbs and flows of drug discovery and development. Our relationship with the tranSMART Foundation is an important milestone for our life science ecosystem,” said Yury Rozenman, Business Development Director, BT for Life Sciences. “Working with tranSMART enables our customers to better manage computing needs without worrying about expensive hardware and software purchases that can negatively impact the bottom line.”

BT for Life Sciences was developed as a secure platform, using BT Cloud Compute, which allows scientists to construct and orchestrate in-silico workflows and data pipelines so that new pharmaceutical targets and drug candidates can be identified. This platform enables research scientists to create global project groups and collaborate using social media tools. It also allows them to securely upload documents, share results and communicate via instant messaging, voice, video or chat.

 Researchers can also analyze results in an environment that segments data and uses qualified hardware components and workflows specific to the pharmaceutical industry, helping them adhere to GxP quality and regulatory compliance requirements.

About BT

BT is one of the world’s leading providers of communications services and solutions, serving customers in more than 170 countries. Its principal activities include the provision of networked IT services globally; local, national and international telecommunications services to its customers for use at home, at work and on the move; broadband, TV and internet products and services; and converged fixed/mobile products and services. BT consists principally of five lines of business: BT Global Services, BT Business, BT Consumer, BT Wholesale and Openreach. For the year ended 31 March 2013, BT Group’s reported revenue was £18,103m with reported profit before taxation of £2,315m.

British Telecommunications plc (BT) is a wholly-owned subsidiary of BT Group plc and encompasses virtually all businesses and assets of the BT Group. BT Group plc is listed on stock exchanges in London and New York. For more information, visit www.btplc.com.

About The tranSMART Foundation

The tranSMART Foundation is a non-profit organization that provides an open-source, cloud-based, data-sharing and analysis platform that enables scientists at universities, disease foundations, pharmaceutical companies, and government agencies around the world to share pre-competitive data in a way that saves money and time in translating research findings into new therapies and diagnostic tools. Founded to steward the tranSMART platform, the Foundation is headquartered in Wakefield, Massachusetts with Centers of Excellence in Ann Arbor, Mich.; London, England; Boston, Mass.; and Amsterdam, Netherlands. The tranSMART Foundation can also be found on the web at www.tranSMARTFoundation.org.

Contacts:

Karen Higgins
A&E Communications, Inc.
610-831-5723
khiggins@aandecomm.com

 

The tranSMART Foundation Appoints Rudy Potenzone to VP of Marketing

Wakefield, Massachusetts – April 7, 2014 – The tranSMART Foundation, a non-profit organization providing a global, open- source knowledge management platform for scientists to share pre-competitive translational research data, today an- nounced that Rudy Potenzone, Ph.D. has been appointed to VP of Marketing. As a seasoned veteran in the life sciences industry, Dr. Potenzone is responsible for elevating the awareness of the tranSMART Foundation’s brand throughout the biotech and pharmaceutical markets.

“Last year we built a strong base for the Foundation with the launch of version 1.1 of the tranSMART open source platform and the growth of our core community,” said Keith Elliston, Ph.D., CEO of the Foundation. “Now, we are in the position to market our platform to the larger community and with Rudy’s marketing expertise, we believe we can reach our goal to increase awareness in the marketplace of the tranSMART platform and its value.”

“The mission of the tranSMART Foundation to enable collaborative translational research through the mobilization of its open source community is a key component for the evolution of translational medicine,” said Dr. Potenzone. “I’m excited to join the tranSMART Foundation team and to lead the marketing efforts that will stimulate growth of the community and increase the use of the tranSMART platform in scientific research.

Dr. Potenzone has spent more than 30 years designing and delivering novel and integrated solutions across the life science, biological and chemical industries. His background includes recent positions at PerkinElmer as the VP of Product Strategy (Informatics); at Microsoft as worldwide pharma industry technology strategist; and president of Lion Biosciences US. Previ- ously, as senior vice president of Research and Development at MDL, he initiated the development of Isentris and Discovery Gate. Prior to that, he was director of New Product Development and Research for Chemical Abstracts, developing SciFinder and SciFinder Scholar.

Dr. Potenzone holds a Ph.D. and an M.S. in macromolecular science from Case Western Reserve University and a B.S. in bio-physics from the University of Pittsburgh.

About The tranSMART Foundation

The tranSMART Foundation is a non-profit organization that provides an open-source, cloud-based, data-sharing and analysis platform that enables scientists at universities, disease foundations, pharmaceutical companies, and government agencies around the world to share pre-competitive data in a way that saves money and time in translating research findings into new therapies and diagnostic tools. Founded to steward the tranSMART platform, the Foundation is headquartered in Wakefield, Massachusetts with Centers of Excellence in Ann Arbor, Mich.; London, England; Boston, Mass.; and Amsterdam, Netherlands. The tranSMART Foundation can also be found on the web at www.tranSMARTFoundation.org.

Contacts: Karen Higgins
A&E Communications, Inc.
610-831-5723
khiggins@aandecomm.com

 

ConvergeHEALTH by Deloitte to Present on tranSMART Open-Source Platform at AMIA Joint Summits on Translational Science

Wakefield, Massachusetts – April 2, 2014 – The tranSMART Foundation, a non-profit organization providing a global, open- source knowledge management platform for scientists to share pre-competitive translational research data, today announced that its Gold-level sponsor, ConvergeHEALTH by Deloitte, will be discussing the value of the tranSMART platform in translational and clinical research in a presentation at the AMIA Joint Summits on Translational Science being held April 7-11, 2014 in San Francisco, Calif.

As part of the Data Sharing and Data Repositories Scientific Session, Elisabeth Scheufele, M.D., M.S., product strategist at ConvergeHEALTH by Deloitte and Clinical Instructor in Medicine at Harvard University will be giving the presentation titled “tranSMART: An Open Source Knowledge Management and High Content Data Analytics Platform” at 1:30 p.m. on Tuesday, April 8.

“As a Gold Partner of the tranSMART Foundation, ConvergeHEALTH by Deloitte has been instrumental in contributing to the development and implementation of the tranSMART platform and to increasing awareness of the power of this knowledge management solution in the life sciences community,” said tranSMART Foundation CEO Keith Elliston. “Attendees at this session will gain a better understanding of the advanced capabilities of the platform and how it can be an effective tool for life scientists conducting translational or clinical research.”

As used in this document, “Deloitte” means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

About The tranSMART Foundation

The tranSMART Foundation is a non-profit organization that provides an open-source, cloud-based, data-sharing and analysis platform that enables scientists at universities, disease foundations, pharmaceutical companies, and government agencies around the world to share pre-competitive data in a way that saves money and time in translating research findings into new therapies and diagnostic tools. Founded to steward the tranSMART platform, the Foundation is headquartered in Wakefield, Massachusetts with Centers of Excellence in Ann Arbor, Mich.; London, England; Boston, Mass.; and Amsterdam, Netherlands. The tranSMART Foundation can also be found on the web at www.tranSMARTFoundation.org.

Contacts: Karen Higgins
A&E Communications, Inc. 610-831-5723 khiggins@aandecomm.com